Signal management in pharmacovigilance and human risk assessment of CpG 7909, integrating embryo-fetal and post-natal developmental toxicity studies in rats and rabbits
Keywords: BW; body weight; CpG; unmethylated 2â² deoxyribo (cytidine-phosphate-guanosine); EFD; embryo-fetal development; EMA; European Medicines Agency; FDA; Food and Drug Administration; G0; day 0 of gestation; GSK; GlaxoSmithKline; HLS; Huntington Life Sciences